EN
Related Links
Press Releases
Home News

Press Releases

CANCER CELL PUBLISHES PHASE 1 LUNG CANCER RESULTS OF RISVUTATUG REZETECAN
Release Date：2026/03/06
Font Size

- Risvutatug rezetecan ARTEMIS-001 Phase 1 Positive Readout Supports Ongoing Phase 3 Development in Refractory SCLC and Additional Pivotal Studies Planned in Lung Cancer.


 

SHANGHAI, March 6, 2026 — Hansoh Pharmaceutical Group Co., Ltd. (“Hansoh Pharma,” 03692.HK) today announced that results from expansion cohorts of ARTEMIS-001 (NCT05276609), a first-in-human Phase 1a/1b study evaluating risvutatug rezetecan (HS-20093 / GSK5764227) in patients with previously treated advanced solid tumors, have been published as a research article in Cancer Cell (Impact Factor: 44.5).



Risvutatug rezetecan is a B7-H3–targeted antibody–drug conjugate (ADC) under clinical development for multiple solid tumors. ARTEMIS-001 evaluated the safety, pharmacokinetics, and antitumor activity of risvutatug rezetecan in 306 patients with previously treated advanced solid tumors, including 259 patients with lung cancer. In the dose-expansion phase, patients with extensive-stage small cell lung cancer (ES-SCLC) or advanced non-small cell lung cancer (NSCLC) received risvutatug rezetecan at 8.0 mg/kg or 10.0 mg/kg intravenously once every three weeks. The primary endpoints included safety and confirmed objective response rate (cORR) per RECIST v1.1.

 

In lung cancer, risvutatug rezetecan demonstrated clinically meaningful activity in heavily pretreated populations. In ES-SCLC (N=65), the cORR was 52.3% in a population in which approximately 60% had received ≥2 prior lines of therapy; median duration of response (DoR) was 7.1 months, median progression-free survival (PFS) was 6.2 months and median overall survival (OS) was 13.0 months. In NSCLC (N=152), the cORR was 22.4%, with over 60% having received ≥2 prior lines of systemic therapy; median DoR was 9.7 months, median PFS was 5.5 months and median OS was 13.7 months. Notably, in patients with adenocarcinoma NSCLC without actionable genomic alterations (AGAs) treated at 8.0 mg/kg, cORR reached 33.3% with a median PFS of 7.0 months. 

 

Across both lung cancer populations, risvutatug rezetecan demonstrated a manageable safety profile. The most frequent grade ≥3 treatment-related adverse events included decreased neutrophil count, decreased white blood cell count and anemia.

 

Based on the overall efficacy and safety findings from ARTEMIS-001, 8.0 mg/kg was selected for Phase 3 development, with confirmatory studies in second-line SCLC underway in China and globally.

 

The strength of the Phase 1 data has supported regulatory recognition in multiple jurisdictions. Risvutatug rezetecan has received Breakthrough Therapy Designation (BTD) from both the U.S. FDA and the China National Medical Products Administration (NMPA) for ES-SCLC following first-line treatment. The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation for adult patients with ES-SCLC who have progressed on or after platinum-based chemotherapy, along with Orphan Drug Designation for lung neuroendocrine carcinoma. In addition, the NMPA has granted BTD for adult patients with NSCLC without actionable genomic alterations following progression on or after platinum-based chemotherapy.

 

About Risvutatug Rezetecan

Risvutatug rezetecan (HS-20093/GSK5764227) is a B7-H3–targeted ADC discovered and developed by Hansoh Pharma. It comprises a fully human anti-B7-H3 monoclonal antibody conjugated to a number of topoisomerase I inhibitor (TOP1i) payloads (an exatecan derivative, HS-9265) via tetrapeptide-based cleavable linkers.

The program has entered Phase 3 clinical development in China for osteosarcoma and SCLC and is also being evaluated in multiple proof-of-concept studies across additional indications, including NSCLC, head and neck cancer, prostate cancer, esophageal squamous cell carcinoma and colorectal cancer.

In December 2023, Hansoh Pharma granted GSK an exclusive worldwide license, excluding Chinese mainland, Hong Kong, Macau and Taiwan, to develop, manufacture and commercialize risvutatug rezetecan. The program is being advanced globally by GSK, with Phase 1 and Phase 3 clinical studies ongoing outside China.


About SCLC and NSCLC

Lung cancer remains the leading cause of cancer-related mortality worldwide, with approximately 2.48 million new cases diagnosed globally in 2022 [1]. SCLC accounts for approximately 15% of cases and is characterized by rapid progression and poor prognosis, with a 5-year survival rate of approximately 3% in extensive-stage disease [2–4]. NSCLC, which represents approximately 85% of cases [5], comprises a heterogeneous group of malignancies driven by diverse molecular alterations [6].

Platinum-based chemotherapy, with or without immunotherapy, remains the standard first-line treatment for ES-SCLC [7,8], while treatment options beyond first-line have limited durability. In NSCLC, targeted therapies and immune checkpoint inhibitors have improved outcomes in selected populations; however, disease progression due to primary or acquired resistance remains common. Significant unmet medical need persists across both SCLC and NSCLC.

 

References

1. World Health Organization. International Agency for Research on Cancer. U.S. Cancer Fact Sheet. Accessed August 2025.

2. Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563-1579. doi:10.1158/1055-9965.EPI-19-0221

3. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. Published 2021 Jan 14. doi:10.1038/s41572-020-00235-0

4. SEER Small Cell Carcinoma of the Lung and Bronchus SEER 5-Year Relative Survival Rates. Data from SEER 2012-2018

5. National Cancer Institute. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. October 2023.

6. Chen, Z.; Fillmore, C.M.; Hammerman, P.S.; Kim, C.F.; Wong, K.K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014, 14, 535-546.

7. Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025;333(21):1906-1917. doi:10.1001/jama.2025.0560

8. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220-2229. doi:10.1056/NEJMoa1809064


About Hansoh Pharma

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).

Statements

1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.

Forward-Looking Statements

This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).